CN1656075A - 喹啉衍生物和其作为5-ht6配体的用途 - Google Patents
喹啉衍生物和其作为5-ht6配体的用途 Download PDFInfo
- Publication number
- CN1656075A CN1656075A CNA038116448A CN03811644A CN1656075A CN 1656075 A CN1656075 A CN 1656075A CN A038116448 A CNA038116448 A CN A038116448A CN 03811644 A CN03811644 A CN 03811644A CN 1656075 A CN1656075 A CN 1656075A
- Authority
- CN
- China
- Prior art keywords
- quinoline
- piperazine
- benzenesulfonyl
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Description
实施例 | Q1 | 一般制备方法 | 原料硫醇 | M+H+ |
18 | 2-Me | 1 | 2-甲基-苯硫醇 | 368 |
19 | 2-OMe | 1 | 2-甲氧基-苯硫醇 | 384 |
20 | 4-Me | 1 | 4-甲基-苯硫醇 | 368 |
21 | 4-F | 2 | 4-氟-苯硫醇 | 372 |
22 | 2-CF3 | 2 | 2-三氟甲基-苯硫醇 | 422 |
实施例 | Q1 | 一般制备方法 | 原料硫醇 | M+H+ |
23 | 2-Me | 1 | 2-甲基-苯硫醇 | 382 |
24 | 2-OMe | 1 | 2-甲氧基-苯硫醇 | 398 |
25 | 4-Me | 1 | 4-甲基-苯硫醇 | 382 |
26 | 4-F | 2 | 4-氟-苯硫醇 | 386 |
27 | 3-F | 2 | 3-氟-苯硫醇 | 386 |
28 | 2-F | 2 | 2-氟-苯硫醇 | 386 |
29 | 4-C1 | 2 | 4-氯-苯硫醇 | 402.404 |
30 | 3-Cl | 1 | 3-氯-苯硫醇 | 402.404 |
31 | 2-CF3 | 2 | 2-三氟甲基-苯硫醇 | 436 |
实施例 | Q1 | 一般制备方法 | 原料硫醇 | M+H+ |
32 | 2-Me | 1 | 2-甲基-苯硫醇 | 382 |
33 | 2-OMe | 1 | 2-甲氧基-苯硫醇 | 398 |
34 | 4-Me | 1 | 4-甲基-苯硫醇 | 382 |
35 | 4-F | 2 | 4-氟-苯硫醇 | 386 |
36 | 3-F | 2 | 3-氟-苯硫醇 | 386 |
37 | 2-F | 2 | 2-氟-苯硫醇 | 386 |
38 | 4-Cl | 2 | 4-氯-苯硫醇 | 402.404 |
39 | 3-Cl | 1 | 3-氯-苯硫醇 | 402.404 |
40 | 2-CF3 | 2 | 2-三氟甲基-苯硫醇 | 436 |
实施例 | R1 | R2 | 胺 | 醛/酮 | M+H+ |
45 | iPr | H | E2 | 丙酮 | 396 |
46 | iBu | H | E2 | 异丁醛 | 410 |
47 | 2,2-二甲基丙基 | H | E2 | 2,2-二甲基丙醛 | 424 |
48 | Me | (R)-Me | E12 | 37%甲醛的甲醇水溶液 | 382 |
49 | Me | (S)-Me | E13 | 37%甲醛的甲醇水溶液 | 382 |
Claims (30)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207289.0 | 2002-03-27 | ||
GB0207289A GB0207289D0 (en) | 2002-03-27 | 2002-03-27 | Novel compounds |
GB0225678A GB0225678D0 (en) | 2002-11-04 | 2002-11-04 | Novel compounds |
GB0225678.2 | 2002-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1656075A true CN1656075A (zh) | 2005-08-17 |
CN1315809C CN1315809C (zh) | 2007-05-16 |
Family
ID=28456035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038116448A Expired - Fee Related CN1315809C (zh) | 2002-03-27 | 2003-03-25 | 喹啉衍生物和其作为5-ht6配体的用途 |
Country Status (28)
Country | Link |
---|---|
US (5) | US7452888B2 (zh) |
EP (2) | EP1956004B1 (zh) |
JP (2) | JP4455064B2 (zh) |
KR (1) | KR101020399B1 (zh) |
CN (1) | CN1315809C (zh) |
AR (1) | AR039127A1 (zh) |
AT (1) | ATE398108T1 (zh) |
AU (1) | AU2003219103B2 (zh) |
BR (1) | BRPI0308696B8 (zh) |
CA (1) | CA2479786C (zh) |
CY (2) | CY1108313T1 (zh) |
DE (1) | DE60321558D1 (zh) |
DK (2) | DK1956004T3 (zh) |
ES (2) | ES2386828T3 (zh) |
HK (1) | HK1074439A1 (zh) |
IL (2) | IL164108A0 (zh) |
IS (1) | IS2599B (zh) |
MX (1) | MXPA04009318A (zh) |
MY (1) | MY138836A (zh) |
NO (1) | NO329319B1 (zh) |
NZ (1) | NZ535239A (zh) |
PL (1) | PL209872B1 (zh) |
PT (2) | PT1956004E (zh) |
RU (1) | RU2309154C9 (zh) |
SI (2) | SI1497266T1 (zh) |
TW (1) | TWI268928B (zh) |
WO (1) | WO2003080580A2 (zh) |
ZA (1) | ZA200407320B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844304A (zh) * | 2010-01-04 | 2012-12-26 | 日本曹达株式会社 | 含氮杂环化合物以及农园艺用杀菌剂 |
CN101687866B (zh) * | 2007-08-07 | 2014-06-04 | Abbvie德国有限责任两合公司 | 用于治疗响应于血色素5-ht6受体调节的疾病的喹啉化合物 |
WO2017202206A1 (zh) * | 2016-05-27 | 2017-11-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1956004B1 (en) * | 2002-03-27 | 2012-06-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
RU2347780C2 (ru) | 2003-02-14 | 2009-02-27 | Уайт | Гетероциклил-3-сульфонилиндазолы в качестве лигандов 5-гидрокситриптамина-6 |
TW200418830A (en) | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
BRPI0412263B1 (pt) | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
GB0322510D0 (en) * | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
GB0322629D0 (en) * | 2003-09-26 | 2003-10-29 | Glaxo Group Ltd | Novel compound |
GB0407025D0 (en) * | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
GB0425548D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Radiolabelled ligands |
GB0426313D0 (en) * | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
AU2006254255A1 (en) | 2005-06-02 | 2006-12-07 | F. Hoffmann-La Roche Ag | 3-methanesulfonylquinolines as GABA-B enhancers |
MX2008001033A (es) | 2005-07-27 | 2008-03-19 | Hoffmann La Roche | Derivados de 4-ariloxi quinolina como moduladores de 5-ht6. |
GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
DE602006009556D1 (de) * | 2005-12-20 | 2009-11-12 | Richter Gedeon Nyrt | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen |
EP2001865A1 (en) | 2006-04-05 | 2008-12-17 | Wyeth a Corporation of the State of Delaware | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
EA017007B1 (ru) | 2007-01-08 | 2012-09-28 | Сувен Лайф Сайенсиз Лимитед | Соединения 5-(гетероциклил)алкил-n-(арилсульфонил)индола и их применение в качестве лигандов 5-ht |
MY156814A (en) * | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
WO2008113818A1 (en) * | 2007-03-21 | 2008-09-25 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
WO2008116831A1 (en) * | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
EA016594B1 (ru) | 2007-05-03 | 2012-06-29 | Сувен Лайф Сайенсиз Лимитед | Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов |
PL2167469T3 (pl) * | 2007-06-18 | 2013-01-31 | Richter Gedeon Nyrt | Pochodne sulfonylochinoliny |
DK2200980T3 (da) | 2007-10-26 | 2011-11-21 | Suven Life Sciences Ltd | Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander |
EP2254564A1 (en) * | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CA2713378A1 (en) * | 2008-02-15 | 2009-08-20 | F. Hoffmann-La Roche Ag | 3-alkyl-piperazine derivatives and uses thereof |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
DK2346847T3 (da) | 2008-09-17 | 2013-08-05 | Suven Life Sciences Ltd | Arylsulfonamidaminforbindelser og deres anvendelse som 5-ht6-ligander |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
EP2448582B1 (en) | 2009-06-29 | 2017-04-19 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
JP5628937B2 (ja) | 2010-01-05 | 2014-11-19 | スベン ライフ サイエンシズ リミティド | 5−ht6受容体リガンドとしてのスルホン化合物 |
RU2443697C1 (ru) * | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения |
KR101250606B1 (ko) * | 2011-01-24 | 2013-04-03 | 이화여자대학교 산학협력단 | 5-ht6 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
AU2012321345B2 (en) | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
RU2500672C1 (ru) * | 2012-10-25 | 2013-12-10 | Андрей Александрович Иващенко | (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения |
US9302992B2 (en) | 2013-04-02 | 2016-04-05 | Annji Pharmaceutical Co., Ltd. | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
CN105452224B (zh) | 2013-04-02 | 2017-12-26 | 安基生技新药股份有限公司 | 作为抗神经退化剂的多官能性喹啉衍生物 |
JP2018519358A (ja) * | 2015-05-07 | 2018-07-19 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | 神経変性疾患を処置する方法 |
RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
AR106515A1 (es) | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
JP7027318B2 (ja) * | 2016-02-05 | 2022-03-01 | ファーネクスト | 神経障害の新規の併用療法 |
WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
WO2018102824A1 (en) * | 2016-12-02 | 2018-06-07 | Axovant Sciences Gmbh | Methods for treating neurodegenerative disease |
KR20210076224A (ko) | 2019-12-13 | 2021-06-24 | 주식회사 에피바이오텍 | 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물 |
KR102281647B1 (ko) * | 2020-12-09 | 2021-07-30 | 메디케어제약 주식회사 | 피페라진-퀴놀린 유도체의 제조방법 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US708469A (en) * | 1901-08-27 | 1902-09-02 | George Lafayette Caldwell | Stroke-regulating mechanism for glass-presses, &c. |
JPH02262627A (ja) | 1988-12-08 | 1990-10-25 | Japan Synthetic Rubber Co Ltd | 有機非線形光学素子 |
SI9200377A (en) * | 1992-12-11 | 1994-06-30 | Krka | Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation |
GB9300147D0 (en) | 1993-01-06 | 1993-03-03 | Minnesota Mining & Mfg | Photothermographic materials |
GB9311790D0 (en) | 1993-06-08 | 1993-07-28 | Minnesota Mining & Mfg | Photothermographic materials |
US5596001A (en) | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
DK122693D0 (da) | 1993-10-29 | 1993-10-29 | Hempels Skibsfarve Fab J C | Marin struktur |
US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
AUPN842196A0 (en) | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
FR2750988B1 (fr) | 1996-07-11 | 1998-09-18 | Adir | Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20010051719A1 (en) | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
DE59803962D1 (de) | 1997-03-25 | 2002-06-06 | Ciba Sc Holding Ag | Polycyclische Verbindungen |
KR20000069311A (ko) | 1997-04-22 | 2000-11-25 | 디르크 반테 | Crf 길항성 퀴노- 및 퀴나졸린 |
AU747026B2 (en) | 1997-05-28 | 2002-05-09 | Aventis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
AU757059B2 (en) | 1997-06-19 | 2003-01-30 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
US6103905A (en) | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
US6376670B1 (en) | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
US6207679B1 (en) | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
HUP0003073A3 (en) | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
DE69906397T2 (de) * | 1998-01-16 | 2004-02-19 | F. Hoffmann-La Roche Ag | Benzosulfonderivate |
GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US6403808B1 (en) | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
WO2000058303A1 (en) | 1999-03-29 | 2000-10-05 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
DE69937372T2 (de) * | 1999-04-21 | 2008-06-26 | Nps Allelix Corp., Mississauga | Piperidin-indol derivate mit 5-ht6 affinität |
WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
MY125942A (en) | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
AU1542201A (en) | 1999-11-05 | 2001-05-14 | Nps Allelix Corp. | Compounds having 5-HT6 receptor antagonist activity |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
US6310212B1 (en) | 2000-03-28 | 2001-10-30 | Neurogen Corporation | 4-substituted quinoline derivatives |
PE20020063A1 (es) | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
GB0021450D0 (en) | 2000-08-31 | 2000-10-18 | Smithkline Beecham Plc | Novel compounds |
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
AU9384701A (en) | 2000-10-02 | 2002-04-15 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
AU9619301A (en) | 2000-10-20 | 2002-04-29 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
AU2005102A (en) | 2000-11-02 | 2002-05-15 | Wyeth Corp | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
AU2002215047A1 (en) | 2000-11-21 | 2002-06-03 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
DE60122767T2 (de) | 2000-11-24 | 2007-09-13 | Smithkline Beecham P.L.C., Brentford | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns |
ES2188344B1 (es) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
KR100600240B1 (ko) | 2001-06-07 | 2006-07-13 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화도를 갖는 신규한 인돌 유도체 |
BR0210411A (pt) | 2001-06-15 | 2004-08-17 | Hoffmann La Roche | Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6 |
ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
BR0211561A (pt) | 2001-08-03 | 2004-11-30 | Upjohn Co | Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos |
US20040242589A1 (en) | 2001-08-07 | 2004-12-02 | Bromidge Steven Mark | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
EP1423106B1 (en) | 2001-08-10 | 2008-12-17 | F. Hoffmann-La Roche Ag | Arylsulfonyl derivatives with 5-ht 6 receptor affinity |
PT2305656E (pt) | 2001-08-31 | 2013-01-10 | Novartis Ag | Isómeros óticos de um metabolito de iloperidona |
SE0103649D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
EP1456178A1 (en) | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
GB0202679D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
JP2005522432A (ja) | 2002-02-05 | 2005-07-28 | グラクソ グループ リミテッド | ニューロン成長の促進方法 |
AU2003206909A1 (en) | 2002-02-13 | 2003-09-04 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
DE10207844A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
EP1478361A2 (en) | 2002-02-22 | 2004-11-24 | PHARMACIA & UPJOHN COMPANY | Arylsulfone derivatives |
EP1956004B1 (en) * | 2002-03-27 | 2012-06-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
ATE346068T1 (de) | 2002-03-27 | 2006-12-15 | Glaxo Group Ltd | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden |
WO2003095434A1 (en) | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
DE10221183A1 (de) | 2002-05-13 | 2003-12-04 | Max Planck Gesellschaft | Phosphatidyl-oligo-glycerine und Strukturanaloga |
RU2323927C2 (ru) | 2002-06-05 | 2008-05-10 | Ф.Хоффманн-Ля Рош Аг | Производные 1-сульфонил-4-аминоалкоксииндола и фармацевтическая композиция, обладающая активностью модулятора 5-нт6 рецептора |
EP1513828A1 (en) | 2002-06-20 | 2005-03-16 | Biovitrum AB | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
ES2287518T3 (es) | 2002-09-17 | 2007-12-16 | F. Hoffmann-La Roche Ag | Indoles 2,7-sustituidos y su empleo como moduladores de 5-ht6. |
ES2311721T3 (es) | 2002-09-17 | 2009-02-16 | F. Hoffmann-La Roche Ag | Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6. |
ATE344030T1 (de) | 2002-10-18 | 2006-11-15 | Hoffmann La Roche | 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität |
AU2003293653B2 (en) | 2002-11-08 | 2009-05-14 | F. Hoffmann-La Roche Ag | Substituted benzoxazinones and uses thereof |
PL377464A1 (pl) | 2002-12-03 | 2006-02-06 | F. Hoffmann-La Roche Ag | Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN |
TW200418830A (en) | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
ATE381334T1 (de) | 2003-03-03 | 2008-01-15 | Hoffmann La Roche | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren |
GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
GB0320320D0 (en) | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
GB0322510D0 (en) | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
GB0322629D0 (en) | 2003-09-26 | 2003-10-29 | Glaxo Group Ltd | Novel compound |
GB0407025D0 (en) | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
GB0411421D0 (en) | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
GB0519765D0 (en) | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
GB0519760D0 (en) | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en active IP Right Grant
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko active IP Right Grant
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
-
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
-
2005
- 2005-06-29 HK HK05105458A patent/HK1074439A1/xx not_active IP Right Cessation
-
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
-
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
-
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
-
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Lifetime
-
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101687866B (zh) * | 2007-08-07 | 2014-06-04 | Abbvie德国有限责任两合公司 | 用于治疗响应于血色素5-ht6受体调节的疾病的喹啉化合物 |
CN102844304A (zh) * | 2010-01-04 | 2012-12-26 | 日本曹达株式会社 | 含氮杂环化合物以及农园艺用杀菌剂 |
CN102844304B (zh) * | 2010-01-04 | 2014-12-31 | 日本曹达株式会社 | 含氮杂环化合物以及农园艺用杀菌剂 |
WO2017202206A1 (zh) * | 2016-05-27 | 2017-11-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物 |
CN108290842A (zh) * | 2016-05-27 | 2018-07-17 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物 |
CN108290842B (zh) * | 2016-05-27 | 2021-04-06 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1656075A (zh) | 喹啉衍生物和其作为5-ht6配体的用途 | |
CN1310915C (zh) | 作为DPP-IV抑制剂的吡啶并(2,1-a)异喹啉衍生物 | |
CN1242995C (zh) | 化合物,它们的用途和制备方法 | |
CN1057083C (zh) | 三环结构1-氨基乙基吡咯衍生物及其制备方法和用途 | |
CN1286815C (zh) | 4-苯胺基喹啉-3-甲酰胺类化合物 | |
CN1289087C (zh) | 作为神经肽y拮抗剂的喹啉衍生物 | |
CN1273469C (zh) | 作为保胎用催产素受体拮抗剂的三环二氮杂䓬 | |
CN1694873A (zh) | 辣椒素受体配体及其治疗用途 | |
CN1072219C (zh) | 二氮杂䓬酮、其生产和用途 | |
CN1906180A (zh) | 新的长效β-2-激动剂及其作为药物的用途 | |
CN1452619A (zh) | 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物 | |
CN100340562C (zh) | 杂环稠合的苯并二噁烷的抗抑郁芳基哌嗪衍生物 | |
CN101039937A (zh) | 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物 | |
CN1030582A (zh) | 苯并吡喃衍生物 | |
CN1129937A (zh) | 作为5ht2c拮抗剂的二氢吲哚衍生物 | |
CN1042133C (zh) | N-取代的氮杂双环庚烷衍生物及其用途 | |
CN1230432C (zh) | 取代的苯基-哌嗪衍生物及其制备和用途 | |
CN1027368C (zh) | 新型取代的喹啉衍生物的制备方法 | |
CN1250542C (zh) | 具有抗肿瘤活性的2-(1h-吲哚-3-基)-2-氧代-乙酰胺 | |
CN1839135A (zh) | 三环δ阿片样物质调节剂 | |
CN1058208A (zh) | 药物化合物 | |
CN87103504A (zh) | 杂环羧酰胺 | |
CN1478092A (zh) | 苯并噁嗪酮衍生物及其制备和应用 | |
CN101031554A (zh) | 苯并嗪和喹喔啉衍生物及用途 | |
CN1531537A (zh) | 用作保胎催产素受体拮抗剂的新型三环吡啶基苯并氮杂�羧酰胺及其衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ROIVANT NEUROSCIENCES LTD. Free format text: FORMER OWNER: GLAXO GROUP LIMITED Effective date: 20150818 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: AXOVANT SCIENCES LTD. Free format text: FORMER NAME: ROIVANT NEUROSCIENCES LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Bermuda Hamilton Patentee after: Akso Aventis science Ltd. Address before: Bermuda Hamilton Patentee before: Roy Aventis neurosciences Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150818 Address after: Bermuda Hamilton Patentee after: Roy Aventis neurosciences Ltd. Address before: British Meader Sykes Patentee before: Glaxo Group Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170203 Address after: Basel, Switzerland Patentee after: Akso Aventis Science Co.,Ltd. Address before: Bermuda Hamilton Patentee before: Akso Aventis science Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070516 Termination date: 20210325 |
|
CF01 | Termination of patent right due to non-payment of annual fee |